Brief: 4DMT Reports Positive Interim Data From 4D-150 Spectra Clinical Trial In DME And Alignment With FDA On Registrational Path
10/01/2025 13:19
Jan 10 (Reuters) - 4D Molecular Therapeutics Inc
FDMT.O :
* 4DMT ANNOUNCES POSITIVE INTERIM DATA FROM 4D-150 SPECTRA
CLINICAL TRIAL IN DME AND ALIGNMENT WITH FDA ON REGISTRATIONAL
PATH
* 4D MOLECULAR THERAPEUTICS INC - 4D-150 WELL TOLERATED WITH
NO
INTRAOCULAR INFLAMMATION OBSERVED
Source text: urn:newsml:reuters.com:*:nGNX9y1cRq
Further company coverage: FDMT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on 4D Molecular Therapeutics
See all news4D Molecular Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
4D Molecular Therapeutics Q2 net loss widens
Brief: 4D Molecular Therapeutics Q2 Net Income USD -72.936 Million Vs. IBES Estimate USD -70.3 Million
4D Molecular Therapeutics Inc expected to post a loss of $1.02 a share - Earnings Preview
Brief: 4d Molecular Therapeutics Says 4D-150 Continues To Be Well Tolerated With No New Safety Findings